非编码RNA在乳腺癌化疗耐药中作用的研究进展

doi:10.11904/j.issn.1002-3070.2023.05.012

摘要/Abstract

摘要： 乳腺癌是一类具有高度异质性的恶性肿瘤。化疗是晚期乳腺癌或乳腺癌术后的重要治疗手段之一。然而继发性耐药的出现削弱了化疗效果,导致患者预后较差。近年来,越来越多的研究证明非编码RNA(non-coding RNA,ncRNA)可通过调控细胞增殖、肿瘤干细胞特性、上皮-间质转化等过程,促进乳腺癌化疗耐药。本文针对ncRNA介导乳腺癌化疗耐药相关机制的研究进行综述。

关键词: 乳腺癌, 非编码RNA, 化疗耐药

Abstract: Breast cancer is a kind of malignant tumor with high heterogeneity.Chemotherapy is one of the important treatments for advanced breast cancer or postoperative breast cancer.However,the emergence of secondary drug resistance weakens the effectiveness of chemotherapy,leading to a poor prognosis for patients.In recent years,more and more studies have shown that non-coding RNA(ncRNA)can promote breast cancer chemotherapy resistance by regulating cell proliferation,tumor stem cell characteristics,epithelial-mesenchymal transition and other processes.This article reviews the research on the mechanism of ncRNA-mediated chemotherapy resistance in breast cancer.

Key words: Breast cancer, Non-coding RNA, Chemotherapy resistance

中图分类号:

R737.9

王新萍, 张自云, 王学东. 非编码RNA在乳腺癌化疗耐药中作用的研究进展[J]. 实用肿瘤学杂志, 2023, 37(5): 454-458.

WANG Xinping, ZHANG Ziyun, WANG Xuedong. Research progress on the roles of non-coding RNA in chemotherapy resistance of breast cancer[J]. Journal of Practical Oncology, 2023, 37(5): 454-458.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2023.05.012

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2023/V37/I5/454

参考文献

1 Yousefi H,Maheronnaghsh M,Molaei F,et al.Long noncoding RNAs and exosomal lncRNAs:classification,and mechanisms in breast cancer metastasis and drug resistance[J].Oncogene,2020,39(5):953-974.
2 Zhang L,Xu X,Su X.Noncoding RNAs in cancer immunity:functions,regulatory mechanisms,and clinical application[J].Mol Cancer,2020,19(1):48.
3 Ambros V.The functions of animal microRNAs[J].Nature,2004,431(7006):350-355.
4 Ponting CP,Oliver PL,Reik W.Evolution and functions of long noncoding RNAs[J].Cell,2009,136(4):629-641.
5 Saaoud F,Drummer IVC,Shao Y,et al.Circular RNAs are a novel type of non-coding RNAs in ROS regulation,cardiovascular metabolic inflammations and cancers[J].Pharmacol Ther,2021,220:107715.
6 Li H,Sun X,Li J,et al.Hypoxia induces docetaxel resistance in triple-negative breast cancer via the HIF-1α/miR-494/survivin signaling pathway[J].Neoplasia,2022,32.
7 Yang Q,Zhao S,Shi Z,et al.Chemotherapy-elicited exosomal miR-378a-3p and miR-378d promote breast cancer stemness and chemoresistance via the activation of EZH2/STAT3 signaling[J].J Exp Clin Cancer Res,2021,40(1):120.
8 Yang W,Gu J,Wang X,et al.Inhibition of circular RNA CDR1as increases chemosensitivity of 5-FU-resistant BC cells through up-regulating miR-7[J].J Cell Mol Med,2019,23(5):3166-3177.
9 Sabatier R,Charafe-Jauffret E,Pierga JY,et al.Stem cells inhibition by bevacizumab in combination with neoadjuvant chemotherapy for breast cancer[J].J Clin Med,2019,8(5):612.
10 Zhang Z,Qiu N,Yin J,et al.SRGN crosstalks with YAP to maintain chemoresistance and stemness in breast cancer cells by modulating HDAC2 expression[J].Theranostics,2020,10(10):4290-4307.
11 Han X,Li M,Xu J,et al.miR-1275 targets MDK/AKT signaling to inhibit breast cancer chemoresistance by lessening the properties of cancer stem cells[J].Int J Biol Sci,2023,19(1):89-103.
12 Cheng S,Huang Y,Lou C,et al.FSTL1 enhances chemoresistance and maintains stemness in breast cancer cells via integrin β3/Wnt signaling under miR-137 regulation[J].Cancer Biol Ther,2019,20(3):328-337.
13 Singh D,Assaraf YG,Gacche RN.Long non-coding RNA mediated drug resistance in breast cancer[J].Drug Resist Updat,2022,63:100851.
14 Armada A,Gomes BC,Viveiros M,et al.Regulation of ABCB1 activity by microRNA-200c and microRNA-203a in breast cancer cells:the quest for microRNAs' involvement in cancer drug resistance[J].Cancer Drug Resist,2019,2(3):897-911.
15 Xie M,Fu Z,Cao J,et al.MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer[J].Biomed Pharmacother,2018,102:286-294.
16 Chen Z,Pan T,Jiang D,et al.The lncRNA-GAS5/miR-221-3p/DKK2 axis modulates ABCB1-mediated ariamycin resistance of breast cancer via the Wnt/β-Catenin signaling pathway[J].Mol Ther Nucleic Acids,2020,19:1434-1448.
17 Wang R,Zhang T,Yang Z,et al.Long non-coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB1[J].J Cell Mol Med,2018,22(9):4068-4075.
18 Tang W,Lu G,Ji Y,et al.Long non-coding RNA PCAT1 sponges miR-134-3p to regulate PITX2 expression in breast cancer[J].Mol Med Rep,2022,25(3):75.
19 Qiao Y,Jin T,Guan S,et al.Long non-coding RNA Lnc-408 promotes invasion and metastasis of breast cancer cell by regulating LIMK1[J].Oncogene,2021,40(24):4198-4213.
20 Zhu M,Wang F,Mi H,et al.Long noncoding RNA MEG3 suppresses cell proliferation,migration and invasion,induces apoptosis and paclitaxel-resistance via miR-4513/PBLD axis in breast cancer cells[J].Cell Cycle,2020,19(23):3277-3288.
21 Zhu L,Wang F,Fan W,et al.LncRNA NEAT1 promotes the taxol resistance of breast cancer via sponging the miR-23a-3p-FOXA1 axis[J].Acta Biochim Biophys Sin(Shanghai),2021,53(9):1198-1206.
22 白仲虎,李璐,戴晓峰.转录因子FOXA1在乳腺癌分子分型中的功能研究[J].生物学杂志,2017,34(1):6.
23 Venkatesh J,Wasson M,Brown J,et al.LncRNA-miRNA axes in breast cancer:novel points of interaction for strategic attack[J].Cancer Lett,2021,509:81-88.
24 Hashemi M,Arani HZ,Orouei S,et al.EMT mechanism in breast cancer metastasis and drug resistance:revisiting molecular interactions and biological functions[J].Biomed Pharmacother,2022,155:113774.
25 Tang L,Chen Y,Chen H,et al.DCST1-AS1 promotes TGF-β-Induced epithelial–mesenchymal transition and enhances chemoresistance in triple-negative breast cancer cells via ANXA1[J].Front Oncol,2020,10:280.
26 Ding J,Wu W,Yang J,et al.Long non-coding RNA MIF-AS1 promotes breast cancer cell proliferation,migration and EMT process through regulating miR-1249-3p/HOXB8 axis[J].Pathol Res Pract,2019,215(7):152376.
27 Saxena M,Hisano M,Neutzner M,et al.The long non-coding RNA ET-20 mediates EMT by impairing desmosomes in breast cancer cells[J].J Cell Sci,2021,134(21):jcs258418.
28 Poursheikhani A,Bahmanpour Z,Razmara E,et al.Non-coding RNAs underlying chemoresistance in gastric cancer[J].Cell Oncol(Dordr),2020,43(6):961-988.
29 Ma L,Zong X.Metabolic symbiosis in chemoresistance:refocusing the role of aerobic glycolysis[J].Front Oncol,2020,10:5.
30 Ma J,Zhao W,Zhang H,et al.Long non-coding RNA ANRIL promotes chemoresistance in triple-negative breast cancer via enhancing aerobic glycolysis[J].Life Sci,2022,306:120810.
31 Orre C,Dieu X,Guillon J,et al.The long non-coding RNA SAMMSON is a regulator of chemosensitivity and metabolic orientation in MCF-7 doxorubicin-resistant breast cancer Cells[J].Biology(Basel),2021,10(11):1156.
32 Wu M,Wen L,Zhou Y,et al.Role of lncRNA AGAP2-AS1 in breast cancer cell resistance to apoptosis by the regulation of MTA1 promoter activity[J].Technol Cancer Res Treat,2022,21:15330338221085360.
33 Zong B,Sun L,Peng Y,et al.HORMAD1 promotes docetaxel resistance in triple negative breast cancer by enhancing DNA damage tolerance[J].Oncol Rep,2021,46(1):138.
34 Sunagawa Y,Yamada S,Sonohara F,et al.Genome-wide identification and characterization of circular RNA in resected hepatocellular carcinoma and background liver tissue[J].Scientific Reports,2021,11(1):6016.
35 Zeng Y,Zhang J,Yue J,et al.The role of DACT family members in tumorigenesis and tumor progression[J].Int J Biol Sci,2022,18(11):4532-4544.
36 Huang S,Xie J,Lei S,et al.CircDUSP1 regulates tumor growth,metastasis,and paclitaxel sensitivity in triple‐negative breast cancer by targeting miR‐761/DACT2 signaling axis[J].Mol Carcinog,2023,62(4):450-463.
37 Zhu M,Wang Y,Wang F,et al.CircFBXL5 promotes the 5-FU resistance of breast cancer via modulating miR-216b/HMGA2 axis[J].Cancer Cell Int,2021,21(1):384.
38 Wang L,Yang X,Zhou F,et al.Circular RNA UBAP2 facilitates the cisplatin resistance of triple-negative breast cancer via microRNA-300/anti-silencing function 1B histone chaperone/PI3K/AKT/mTOR axis[J].Bioengineered,2022,13(3):7197-7208.

[1]	薛羽婷, 毛雄辉, 孙冀, 苑振楠. 长链非编码RNA LINC-PINT通过Hippo/YAP信号通路在缺氧诱导的头颈部鳞状细胞癌药物敏感性中的作用研究[J]. 实用肿瘤学杂志, 2023, 37(6): 466-471.
[2]	冯楚然, 曹剑钊, 陈子印, 张大昕, 鲁海玲. 乳腺癌放射性心脏损伤及其预防措施的研究进展[J]. 实用肿瘤学杂志, 2023, 37(6): 513-518.
[3]	赵诗璐, 庞达. 乳腺癌预后相关基因的生物信息学筛选与分析[J]. 实用肿瘤学杂志, 2023, 37(5): 422-428.
[4]	初思彤, 许庆勇. 三阴性乳腺癌免疫治疗耐药机制的研究进展[J]. 实用肿瘤学杂志, 2023, 37(5): 449-453.
[5]	鲁泓男, 夏冰舒, 乔坤, 张世园, 黄元夕, 鲁祥石. GAS1与乳腺癌免疫治疗及药物敏感性的关系[J]. 实用肿瘤学杂志, 2023, 37(4): 351-359.
[6]	陈飞, 王颖, 曾传琴. B7-H4在乳腺癌组织中的表达及其与患者新辅助化疗后腋窝淋巴结转移的相关性分析[J]. 实用肿瘤学杂志, 2023, 37(4): 360-366.
[7]	李福程, 贾斯媛, 巴玉玲, 罗丹利, 肖敏. 免疫检查点抑制剂在早期乳腺癌新辅助治疗中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(4): 367-371.
[8]	马艳玲, 钱立庭, 魏东华, 尹惠萍, 张娟, 张小鹏. 2014—2017年安徽省合肥市城市乳腺癌高危人群筛查率及其影响因素分析[J]. 实用肿瘤学杂志, 2023, 37(3): 200-206.
[9]	隋世尧, 郑玮, 杨子涵, 庞达. lncRNA SNHG4通过EP300-SNHG4-GPX4轴抑制乳腺癌细胞铁死亡[J]. 实用肿瘤学杂志, 2023, 37(3): 215-223.
[10]	张庆怀, 韩阿蒙, 杨森, 李秀梅, 赵健鑫, 张彦秋. 乳腺癌患者保乳术后五种放疗技术的疗效比较研究[J]. 实用肿瘤学杂志, 2023, 37(3): 224-229.
[11]	杨帅, 王新恒, 吴佳乐, 付子彤, 魏博, 杨灵冰, 许守平. 单细胞测序技术在乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(3): 287-292.
[12]	张馨, 吴羡美, 李虹, 刘晓舟, 孔德文, 陈琢. 1990—2019年中国女性人群归因于代谢危险因素的乳腺癌疾病负担[J]. 实用肿瘤学杂志, 2023, 37(2): 107-111.
[13]	刘欣欣, 马西元, 缪美琪, 王语晴, 陈晶. IL-6及其受体在乳腺癌治疗中的作用研究进展[J]. 实用肿瘤学杂志, 2023, 37(2): 149-154.
[14]	冯诚天, 黄芙蓉, 姜永冬. 脂质代谢与乳腺癌曲妥珠单抗耐药性机制的相关性研究[J]. 实用肿瘤学杂志, 2023, 37(2): 155-159.
[15]	周兴安, 苏尼特, 武旭, 达林泰, 德乐黑巴特尔. 外泌体lncRNA在鳞癌中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(2): 160-163.